---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-037198"
form_type: "8-K"
ticker: null
cik: "0001082038"
company_name: "DURECT CORP"
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T06:57:20.184837+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DURECT reports Q4/FY2023 results; larsucosterol shows mortality reduction in Phase 2b AH trial

## Summary
- Q4 2023 total revenues $2.7M, net loss $1.4M vs $3.3M and $10.5M in Q4 2022.
- Full year 2023 revenues $8.5M, net loss $27.6M vs $19.3M and $35.3M in 2022; cash $29.8M.
- Larsucosterol 30mg reduced 90-day mortality 41% (p=0.068); 90mg reduced 35% (p=0.124).
- In U.S. patients, mortality reductions of 57% (30mg, p=0.014) and 58% (90mg, p=0.008).
- Entered co-marketing agreement with Charles River for ALZET osmotic pumps in U.S./Canada.

## SEC filing metadata
- accession: 0000950170-24-037198
- form_type: 8-K
- cik: 0001082038
- company_name: DURECT CORP
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082038/000095017024037198/0000950170-24-037198-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082038/000095017024037198/drrx-20240327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-037198
- JSON: https://secwatch.observer/filing/0000950170-24-037198.json
- Plain text: https://secwatch.observer/filing/0000950170-24-037198.txt

## Key facts
- Earnings Releases
  DURECT CORP reported fourth quarter and full year 2023 results: revenue $2.7 million, net income net loss was $1.4 million.
  - Period: fourth quarter and full year 2023
  - Revenue: $2.7 million
  - Net income: net loss was $1.4 million
  - Result: reported results
  source text: Total revenues were $2.7 million and net loss was $1.4 million for the three months ended December 31, 2023 compared to total revenues of $3.3 million and net loss of $10.5 million for the three months ended December 31, 2022. Total revenues were $8.5 million and net loss was $27.6 million for the year ended December 31, 2023, compared to total revenues of $19.3 million and net loss of $35.3 million for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082038/000095017024037198/0000950170-24-037198-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.